Blair William & CO Vertex Pharmaceuticals Inc Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Blair William & CO holds 91,316 shares of VRTX stock, worth $37.3 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

91,316

Previous 89,108 2.48%

Holding current value

$37.3 Million

Previous $41.8 Million 1.68%

% of portfolio

0.13%

Previous 0.13%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$460.0 - $505.78 $1.02 Million - $1.12 Million	2,208 Added 2.48%	91,316 $42.5 Million
Q2 2024 Aug 12, 2024	BUY	$392.81 - $485.53 $7.15 Million - $8.84 Million	18,197 Added 25.66%	89,108 $41.8 Million
Q1 2024 May 09, 2024	BUY	$407.69 - $446.08 $2.83 Million - $3.09 Million	6,937 Added 10.84%	70,911 $29.6 Million
Q4 2023 Feb 12, 2024	BUY	$343.0 - $410.68 $15.5 Million - $18.5 Million	45,128 Added 239.46%	63,974 $26 Million
Q3 2023 Nov 09, 2023	BUY	$338.18 - $362.46 $196,482 - $210,589	581 Added 3.18%	18,846 $6.55 Million
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $22,952 - $25,689	73 Added 0.4%	18,265 $6.43 Million
Q1 2023 May 12, 2023	BUY	$283.23 - $323.1 $155,210 - $177,058	548 Added 3.11%	18,192 $5.73 Million
Q4 2022 Feb 10, 2023	SELL	$285.76 - $321.48 $48,293 - $54,330	-169 Reduced 0.95%	17,644 $5.1 Million
Q3 2022 Nov 09, 2022	SELL	$273.83 - $305.53 $38,883 - $43,385	-142 Reduced 0.79%	17,813 $5.16 Million
Q2 2022 Aug 10, 2022	SELL	$234.96 - $292.55 $135,806 - $169,093	-578 Reduced 3.12%	17,955 $5.06 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $1.1 Million - $1.29 Million	-4,956 Reduced 21.1%	18,533 $4.84 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $1.28 Million - $1.62 Million	7,239 Added 44.55%	23,489 $5.16 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $1.18 Million - $1.32 Million	-6,500 Reduced 28.57%	16,250 $2.95 Million
Q2 2021 Aug 12, 2021	SELL	$187.49 - $221.1 $616,654 - $727,197	-3,289 Reduced 12.63%	22,750 $4.59 Million
Q1 2021 May 13, 2021	SELL	$207.02 - $241.31 $490,637 - $571,904	-2,370 Reduced 8.34%	26,039 $5.6 Million
Q4 2020 Feb 09, 2021	SELL	$207.01 - $276.09 $893,455 - $1.19 Million	-4,316 Reduced 13.19%	28,409 $6.71 Million
Q3 2020 Nov 06, 2020	SELL	$255.65 - $303.1 $4,346 - $5,152	-17 Reduced 0.05%	32,725 $8.91 Million
Q2 2020 Aug 12, 2020	BUY	$225.48 - $295.8 $1.2 Million - $1.57 Million	5,319 Added 19.4%	32,742 $9.51 Million
Q1 2020 May 11, 2020	BUY	$199.77 - $247.81 $26,968 - $33,454	135 Added 0.49%	27,423 $6.53 Million
Q4 2019 Feb 13, 2020	BUY	$166.71 - $223.91 $824,380 - $1.11 Million	4,945 Added 22.13%	27,288 $5.98 Million
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $229,896 - $258,745	-1,383 Reduced 5.83%	22,343 $3.79 Million
Q2 2019 Aug 13, 2019	BUY	$164.61 - $190.37 $899,922 - $1.04 Million	5,467 Added 29.94%	23,726 $4.35 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $1.69 Million - $2.01 Million	10,327 Added 130.19%	18,259 $3.36 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $253,537 - $320,798	1,669 Added 26.65%	7,932 $1.31 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $7,883 - $9,058	47 Added 0.76%	6,263 $1.21 Million
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $22,878 - $26,683	157 Added 2.59%	6,216 $1.06 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $6,367 - $7,439	42 Added 0.7%	6,059 $987,000
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $1,921 - $2,177	14 Added 0.23%	6,017 $902,000
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $889,224 - $973,926	6,003	6,003 $913,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account